关于 Hao 等人撰写的《重症发热伴血小板减少综合征患者病毒性心肌炎的患病率和影响》一文,该文由美国医学科学院(NIU)医学研究中心出版。

IF 6.8 3区 医学 Q1 VIROLOGY Journal of Medical Virology Pub Date : 2024-09-04 DOI:10.1002/jmv.29908
Neng Wang, Shuai Tao, Liang Chen
{"title":"关于 Hao 等人撰写的《重症发热伴血小板减少综合征患者病毒性心肌炎的患病率和影响》一文,该文由美国医学科学院(NIU)医学研究中心出版。","authors":"Neng Wang,&nbsp;Shuai Tao,&nbsp;Liang Chen","doi":"10.1002/jmv.29908","DOIUrl":null,"url":null,"abstract":"<p>We read with great interest the article by Hao et al. titled “Prevalence and Impact of Viral Myocarditis in Patients with Severe Fever with Thrombocytopenia Syndrome.”<span><sup>1</sup></span> The study utilized a retrospective analysis to investigate the prevalence and impact of viral myocarditis in patients with Severe Fever with Thrombocytopenia Syndrome (SFTS). The authors conducted a comprehensive dynamic analysis, comparing epidemiological data, clinical symptoms, electrocardiograms, echocardiograms, and laboratory test results between fatal and nonfatal cases. The results revealed a significantly higher incidence of viral myocarditis in the fatal group, suggesting that viral myocarditis is an important early risk factor for prognosis. While the study provides valuable insights into the high prevalence of viral myocarditis and its significant impact on prognosis in SFTS patients, several limitations warrant further discussion.</p><p>Firstly, the study primarily focused on the impact of myocarditis on prognosis, but failed to assess other potential factors, such as age, underlying conditions, and comorbidities, which could influence prognosis.<span><sup>2</sup></span> The onset of cardiac abnormalities in SFTS patients might be attributed to comorbidities. Previous studies have identified hypertension and type 2 diabetes as known risk factors for cardiovascular diseases.<span><sup>3, 4</sup></span> Moreover, the presence of underlying cardiac conditions can adversely affect patient prognosis. Secondly, potential biases exist in the data collection process. Although the authors mentioned that the data were obtained from two different hospitals, they did not provide detailed information regarding the differences in patient management and treatment approaches between these hospitals. This may impact the generalizability and external validity of the study results. Thirdly, we observed inconsistencies in the study's methodology and results. The study described a dynamic analysis of risk factors associated with mortality (Table 2), but employed univariate Cox regression to assess these factors, neglecting potential interactions and confounding variables. Additionally, the authors used odds ratios (OR) instead of hazard ratios (HR) to evaluate risk coefficients, which is less appropriate for survival analysis. Furthermore, we noticed that the β-values and standard errors (SE) for CK on Day 9 and Day 10 were both zero, yet the corresponding p-values were &lt;0.05. This is unusual, as β-values equal to zero typically indicate no association between the variable and risk, while SE values equal to zero imply complete certainty in the estimate, which is statistically unlikely. We recommend the authors reevaluate their statistical analysis to ensure the accuracy of their results. Fourthly, the authors selected 18 variables associated with myocarditis prognosis and investigated their dynamic changes throughout the disease course. However, we identified the variables Lipase on Day 9 and WBC and Neutrophils on Day 11, which seemed to be inconsistent with the variables presented in Figure 2. Lastly, in Table 3 comparing patients with fulminant myocarditis, the significant difference in sample size between the fatal (2/32) and nonfatal (1/151) groups raises concerns about the comparability and interpretation of the results. The small number of positive cases may also introduce random errors, affecting the robustness of the study findings.</p><p>In summary, this study provides valuable insights into the prevalence and impact of viral myocarditis in SFTS patients. However, addressing these limitations would enhance the reliability and clinical applicability of the findings. Further research is necessary to confirm and expand these results, which have the potential to inform clinical decision-making and patient management strategies.</p><p><b>Neng Wang:</b> Writing—original draft; visualization; conceptualization. <b>Shuai Tao:</b> Writing—original draft; visualization; conceptualization. <b>Liang Chen:</b> Writing—review and editing; supervision; conceptualization.</p><p>The authors declare no conflict of interest.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Regarding the article prevalence and impact of viral myocarditis in patients with severe fever with thrombocytopenia syndrome by Hao et al\",\"authors\":\"Neng Wang,&nbsp;Shuai Tao,&nbsp;Liang Chen\",\"doi\":\"10.1002/jmv.29908\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We read with great interest the article by Hao et al. titled “Prevalence and Impact of Viral Myocarditis in Patients with Severe Fever with Thrombocytopenia Syndrome.”<span><sup>1</sup></span> The study utilized a retrospective analysis to investigate the prevalence and impact of viral myocarditis in patients with Severe Fever with Thrombocytopenia Syndrome (SFTS). The authors conducted a comprehensive dynamic analysis, comparing epidemiological data, clinical symptoms, electrocardiograms, echocardiograms, and laboratory test results between fatal and nonfatal cases. The results revealed a significantly higher incidence of viral myocarditis in the fatal group, suggesting that viral myocarditis is an important early risk factor for prognosis. While the study provides valuable insights into the high prevalence of viral myocarditis and its significant impact on prognosis in SFTS patients, several limitations warrant further discussion.</p><p>Firstly, the study primarily focused on the impact of myocarditis on prognosis, but failed to assess other potential factors, such as age, underlying conditions, and comorbidities, which could influence prognosis.<span><sup>2</sup></span> The onset of cardiac abnormalities in SFTS patients might be attributed to comorbidities. Previous studies have identified hypertension and type 2 diabetes as known risk factors for cardiovascular diseases.<span><sup>3, 4</sup></span> Moreover, the presence of underlying cardiac conditions can adversely affect patient prognosis. Secondly, potential biases exist in the data collection process. Although the authors mentioned that the data were obtained from two different hospitals, they did not provide detailed information regarding the differences in patient management and treatment approaches between these hospitals. This may impact the generalizability and external validity of the study results. Thirdly, we observed inconsistencies in the study's methodology and results. The study described a dynamic analysis of risk factors associated with mortality (Table 2), but employed univariate Cox regression to assess these factors, neglecting potential interactions and confounding variables. Additionally, the authors used odds ratios (OR) instead of hazard ratios (HR) to evaluate risk coefficients, which is less appropriate for survival analysis. Furthermore, we noticed that the β-values and standard errors (SE) for CK on Day 9 and Day 10 were both zero, yet the corresponding p-values were &lt;0.05. This is unusual, as β-values equal to zero typically indicate no association between the variable and risk, while SE values equal to zero imply complete certainty in the estimate, which is statistically unlikely. We recommend the authors reevaluate their statistical analysis to ensure the accuracy of their results. Fourthly, the authors selected 18 variables associated with myocarditis prognosis and investigated their dynamic changes throughout the disease course. However, we identified the variables Lipase on Day 9 and WBC and Neutrophils on Day 11, which seemed to be inconsistent with the variables presented in Figure 2. Lastly, in Table 3 comparing patients with fulminant myocarditis, the significant difference in sample size between the fatal (2/32) and nonfatal (1/151) groups raises concerns about the comparability and interpretation of the results. The small number of positive cases may also introduce random errors, affecting the robustness of the study findings.</p><p>In summary, this study provides valuable insights into the prevalence and impact of viral myocarditis in SFTS patients. However, addressing these limitations would enhance the reliability and clinical applicability of the findings. Further research is necessary to confirm and expand these results, which have the potential to inform clinical decision-making and patient management strategies.</p><p><b>Neng Wang:</b> Writing—original draft; visualization; conceptualization. <b>Shuai Tao:</b> Writing—original draft; visualization; conceptualization. <b>Liang Chen:</b> Writing—review and editing; supervision; conceptualization.</p><p>The authors declare no conflict of interest.</p>\",\"PeriodicalId\":16354,\"journal\":{\"name\":\"Journal of Medical Virology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jmv.29908\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Virology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jmv.29908","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

我们饶有兴趣地阅读了 Hao 等人撰写的题为 "病毒性心肌炎在严重发热伴血小板减少综合征(SFTS)患者中的发病率和影响 "1 的文章。该研究采用回顾性分析方法,调查了病毒性心肌炎在严重发热伴血小板减少综合征(SFTS)患者中的发病率和影响。作者进行了全面的动态分析,比较了死亡病例和非死亡病例的流行病学数据、临床症状、心电图、超声心动图和实验室检查结果。结果显示,死亡病例中病毒性心肌炎的发病率明显高于非死亡病例,这表明病毒性心肌炎是影响预后的重要早期风险因素。首先,该研究主要关注心肌炎对预后的影响,但未能评估其他可能影响预后的潜在因素,如年龄、基础疾病和合并症。以往的研究发现,高血压和 2 型糖尿病是心血管疾病的已知危险因素。其次,数据收集过程中可能存在偏差。虽然作者提到数据是从两家不同的医院获得的,但他们并没有详细说明这两家医院在患者管理和治疗方法上的差异。这可能会影响研究结果的普遍性和外部有效性。第三,我们发现该研究的方法和结果不一致。该研究对与死亡率相关的风险因素进行了动态分析(表 2),但采用了单变量 Cox 回归来评估这些因素,忽略了潜在的相互作用和混杂变量。此外,作者使用几率比(OR)而不是危险比(HR)来评估风险系数,这对于生存分析不太合适。此外,我们注意到,第 9 天和第 10 天 CK 的 β 值和标准误差 (SE) 均为零,但相应的 p 值却为 0.05。这很不寻常,因为β值等于零通常表示变量与风险之间没有关联,而SE值等于零意味着估计值完全确定,这在统计学上是不可能的。我们建议作者重新评估他们的统计分析,以确保结果的准确性。第四,作者选择了 18 个与心肌炎预后相关的变量,并调查了它们在整个病程中的动态变化。然而,我们发现第 9 天的脂肪酶变量和第 11 天的白细胞和中性粒细胞变量似乎与图 2 中的变量不一致。最后,表 3 对暴发性心肌炎患者进行了比较,致命组(2/32)和非致命组(1/151)之间样本量的显著差异令人担忧结果的可比性和解释。总之,这项研究为了解病毒性心肌炎在 SFTS 患者中的发病率和影响提供了宝贵的见解。然而,解决这些局限性将提高研究结果的可靠性和临床适用性。有必要开展进一步研究,以确认和扩展这些结果,这些结果有可能为临床决策和患者管理策略提供参考:写作-原稿;视觉化;概念化。陶帅陶帅:撰写-原稿;视觉化;概念化。陈亮:撰写-审阅和编辑;指导;构思。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Regarding the article prevalence and impact of viral myocarditis in patients with severe fever with thrombocytopenia syndrome by Hao et al

We read with great interest the article by Hao et al. titled “Prevalence and Impact of Viral Myocarditis in Patients with Severe Fever with Thrombocytopenia Syndrome.”1 The study utilized a retrospective analysis to investigate the prevalence and impact of viral myocarditis in patients with Severe Fever with Thrombocytopenia Syndrome (SFTS). The authors conducted a comprehensive dynamic analysis, comparing epidemiological data, clinical symptoms, electrocardiograms, echocardiograms, and laboratory test results between fatal and nonfatal cases. The results revealed a significantly higher incidence of viral myocarditis in the fatal group, suggesting that viral myocarditis is an important early risk factor for prognosis. While the study provides valuable insights into the high prevalence of viral myocarditis and its significant impact on prognosis in SFTS patients, several limitations warrant further discussion.

Firstly, the study primarily focused on the impact of myocarditis on prognosis, but failed to assess other potential factors, such as age, underlying conditions, and comorbidities, which could influence prognosis.2 The onset of cardiac abnormalities in SFTS patients might be attributed to comorbidities. Previous studies have identified hypertension and type 2 diabetes as known risk factors for cardiovascular diseases.3, 4 Moreover, the presence of underlying cardiac conditions can adversely affect patient prognosis. Secondly, potential biases exist in the data collection process. Although the authors mentioned that the data were obtained from two different hospitals, they did not provide detailed information regarding the differences in patient management and treatment approaches between these hospitals. This may impact the generalizability and external validity of the study results. Thirdly, we observed inconsistencies in the study's methodology and results. The study described a dynamic analysis of risk factors associated with mortality (Table 2), but employed univariate Cox regression to assess these factors, neglecting potential interactions and confounding variables. Additionally, the authors used odds ratios (OR) instead of hazard ratios (HR) to evaluate risk coefficients, which is less appropriate for survival analysis. Furthermore, we noticed that the β-values and standard errors (SE) for CK on Day 9 and Day 10 were both zero, yet the corresponding p-values were <0.05. This is unusual, as β-values equal to zero typically indicate no association between the variable and risk, while SE values equal to zero imply complete certainty in the estimate, which is statistically unlikely. We recommend the authors reevaluate their statistical analysis to ensure the accuracy of their results. Fourthly, the authors selected 18 variables associated with myocarditis prognosis and investigated their dynamic changes throughout the disease course. However, we identified the variables Lipase on Day 9 and WBC and Neutrophils on Day 11, which seemed to be inconsistent with the variables presented in Figure 2. Lastly, in Table 3 comparing patients with fulminant myocarditis, the significant difference in sample size between the fatal (2/32) and nonfatal (1/151) groups raises concerns about the comparability and interpretation of the results. The small number of positive cases may also introduce random errors, affecting the robustness of the study findings.

In summary, this study provides valuable insights into the prevalence and impact of viral myocarditis in SFTS patients. However, addressing these limitations would enhance the reliability and clinical applicability of the findings. Further research is necessary to confirm and expand these results, which have the potential to inform clinical decision-making and patient management strategies.

Neng Wang: Writing—original draft; visualization; conceptualization. Shuai Tao: Writing—original draft; visualization; conceptualization. Liang Chen: Writing—review and editing; supervision; conceptualization.

The authors declare no conflict of interest.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Medical Virology
Journal of Medical Virology 医学-病毒学
CiteScore
23.20
自引率
2.40%
发文量
777
审稿时长
1 months
期刊介绍: The Journal of Medical Virology focuses on publishing original scientific papers on both basic and applied research related to viruses that affect humans. The journal publishes reports covering a wide range of topics, including the characterization, diagnosis, epidemiology, immunology, and pathogenesis of human virus infections. It also includes studies on virus morphology, genetics, replication, and interactions with host cells. The intended readership of the journal includes virologists, microbiologists, immunologists, infectious disease specialists, diagnostic laboratory technologists, epidemiologists, hematologists, and cell biologists. The Journal of Medical Virology is indexed and abstracted in various databases, including Abstracts in Anthropology (Sage), CABI, AgBiotech News & Information, National Agricultural Library, Biological Abstracts, Embase, Global Health, Web of Science, Veterinary Bulletin, and others.
期刊最新文献
Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study BK Polyomavirus Infection of Bladder Microvascular Endothelial Cells Leads to the Activation of the cGAS-STING Pathway Fourth-Generation HIV Rapid Tests: Enhanced Sensitivity and Reduced Diagnostic Window for HIV-1 Primary Infection Screening Torque Teno Virus Control by the Classical Pathway of Complement Activation-A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab. Stimulator of interferon genes (STING) inhibits coronavirus infection by disrupting viral replication organelles
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1